RxDoctor Payments Data

David Throneburg, OD

Optometrist · Southern Pines, NCNPI 1144211483

Payments from drug & device makers

$1,989in general payments, 2019–2025

Across 83 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$456
  • Sun Pharmaceutical Industries Inc.$281
  • AbbVie$273
  • Biotissue Holdings Inc.$256
  • Mallinckrodt Hospital Products Inc.$187
  • Bausch & Lomb Americas Inc.$180
  • plus $356 from 9 others

What the payments were for

  • Food & beverage$1,88295%
  • Education$1075%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,989 in reported general payments places this provider in the 65th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$350,647
Medicare patients
1,768
Services billed
4,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine107$130,647
Alphagan PBrimonidine Tartrate191$75,988
LumiganBimatoprost160$67,040
XiidraLifitegrast27$28,150
Brimonidine Tartrate431$19,449
CombiganBrimonidine Tartrate/Timolol63$16,157
MieboPerfluorohexyloctane/Pf11$15,989
SimbrinzaBrinzolamide/Brimonidine Tart41$10,442
VyzultaLatanoprostene Bunod27$10,166
Loteprednol Etabonate46$9,247
Prednisolone Acetate163$8,159
Latanoprost498$7,269
Fluorometholone58$5,769
ZirganGanciclovir12$5,406
TafluprostTafluprost/Pf26$5,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan, Combigan$273$289,833521 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan$180$59,71277 claims
AlconSimbrinza$456$10,44241 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$118$9,24746 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →